Bristol Myers Squibb chief executive Chris Boerner said the United States' lead in launching new medicines was 'not a birthright,' as the country lost its measles elimination status on Tuesday, 17 November.

The Pan American Health Organization (PAHO) said the US had experienced continuous measles transmission for more than a year. By 12 November, the country had recorded 5,412 cases, its highest annual total in more than three decades.

Speaking at the Fortune 500 Innovation Forum in Detroit, Boerner said 90% of new medicines were launched in the US, often two to three years before reaching other wealthy countries, Fortune reported. He did not name Health Secretary Robert F Kennedy Jr or identify a specific policy.

The US first gained measles elimination status in 2000. The designation does not mean a country has no measles cases. It means locally transmitted infections or outbreaks have not continued for 12 months or longer.

What the Measles Setback Means for US Medicine

Bristol Myers Squibb chief executive Chris Boerner said the US pharmaceutical sector's position was supported by public-private partnerships involving the National Institutes of Health, the biotechnology industry, access to capital and the Food and Drug Administration. He also cited respect for science as a factor, Fortune reported.

Boerner said weakening parts of that system could affect the country's ability to develop advanced therapies, including vaccines. Asked about his personal reaction, he described the situation as troubling, Fortune reported.

PAHO Director Jarbas Barbosa said the loss of measles elimination status reflected prolonged virus transmission and increased risks of preventable illness, hospitalisation and death. He said the US, Mexico and Bolivia were taking steps to strengthen vaccination, surveillance and outbreak response.

The Centers for Disease Control and Prevention (CDC) said about a third of US measles cases this year were linked to outbreaks that began in 2025. It had recorded more than 590 hospitalisations. The US reported 2,242 cases in 2025.

Pennsylvania reported more than 1,500 infections and seven measles-related deaths, according to state health officials. Wisconsin reported two child deaths, while New York recorded its first measles-associated death in more than 30 years. CBS News reported that many recent cases had occurred in largely unvaccinated Amish or Mennonite communities.

Falling Coverage Complicates the Route Back

CDC data cited by Fortune shows that 92.4% of US kindergarten children received the measles, mumps and rubella (MMR) vaccine in the 2025-26 school year. The rate was 95.2% in 2019-20. Vaccine exemptions reached a record 4.2%.

Almost all reported cases involved people who were unvaccinated or whose vaccination status was unknown. Two doses of the MMR vaccine are 97% effective against measles. Babies too young to be vaccinated, pregnant women and people with weakened immune systems are among those who may rely on community immunity for protection.

PAHO said the US must submit a corrective action plan and demonstrate 12 months without transmission of the same virus strain to regain its elimination status. Daniel Salas, PAHO's immunisation programme executive, said the plan was expected in the coming weeks.

CDC Director Erica Schwartz said the agency remained focused on stopping outbreaks. 'The measles elimination designation is not what protects Americans, vaccination does,' she said in a statement, adding that $100 million (£76 million) had been invested in state and local health departments.

Health Secretary Robert F Kennedy Jr said the administration would work to regain the designation and that he continued to recommend MMR vaccination. Health experts have criticised his past public doubts about vaccine safety, saying they could undermine confidence in vaccination.